Substance / Medication

Fedratinib

Overview

Active Ingredient
fedratinib
RxNorm CUI
2197490

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Chen Yizhe, Wyatt David, Attanasio Massimo et al. · Cancer Chemother Pharmacol · 2024
PMID: 37955741RCTFull text (PMC)
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.
Masarova Lucia, Verstovsek Srdan, Palandri Francesca et al. · Future Oncol · 2025
PMID: 40476514ObservationalFull text (PMC)
Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti Francesco, Lou Youbei, Chevli Manoj et al. · Future Oncol · 2024
PMID: 37991002ObservationalFull text (PMC)
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Ogasawara Ken, Zhou Simon, Krishna Gopal et al. · Cancer Chemother Pharmacol · 2019
PMID: 31444617ObservationalFull text (PMC)
Fedratinib-Associated Uveitis Effectively Treated With Sub-Tenon's Triamcinolone Acetonide Injection: A Case Report.
Saitoh Akira, Saitoh Ayumi K, Daizumoto Erina et al. · Cureus · 2025
PMID: 40276423Case ReportFull text (PMC)
A Case Report of Fedratinib-Associated Uveitis.
Evans William, Mathew Christina, Richardson-May James et al. · Cureus · 2024
PMID: 38361691Case ReportFull text (PMC)
Fedratinib-induced orbital inflammation.
Lee John Y, Gallo Ryan A, Vu Daniel M et al. · Orbit · 2022
PMID: 33243070Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fedratinib (substance)
SNOMED CT
789359000
UMLS CUI
C3886623
RxNorm CUI
2197490

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.